GlaxoSmithKline Plc said that it will take its $13 per share cash offer for Human Genome Sciences Inc directly to shareholders and will not participate in that company’s strategic review. The unsolicited bid is valued at about $2.6 billion. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
